Methods for evaluating tissue morphogenesis and activity

• US 7,147,839 B2
• Filed: 05/29/1998
• Issued: 12/12/2006
• Est. Priority Date: 05/29/1998
• Status: Expired due to Fees

• Current Assignee: Mariel Therapeutics, Inc.
• Original Assignee: Curis, Inc.
• Inventors: Cohen, Charles M., Sampath, Kuber T.
• Primary Examiner(s): Romeo, David S
• Assistant Examiner(s): Gamett, Daniel C
• Application Number:
  US09/423,943
• Publication Number:
  US 20030109686A1
• Time in Patent Office: 3,119 Days
• Field of Search: 514/12, 514/2, 435/1.1, 435/7.21
• US Class Current: 424/9.2
• CPC Class Codes: A61K 38/1875 Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: C07K 14/51 Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: G01N 33/74 involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Abstract

The present invention is based on the discovery that a true tissue morphogen such as OP-1 provided systemically, alone in its mature dimeric form, or as part of a soluble complex, can induce new replacement tissue regeneration at a localized, permissive defect site distal to the site of administration. Specifically, systemically administered protein is sufficient to induce formation of new functional replacement tissue, sufficient to repair a local defect in a tissue, including skeletal or orthopedic tissues, liver, pancreas, lung, cardiac, renal, uterine, intestinal, gastrointestinal tissue. (As used herein, “orthopedic” or “skeletal” or “joint” or “chondrogenic” tissue is understood to encompass the skeletal and skeletal joint tissues: bone, cartilage, tendon, ligament, and synovial membrane tissues.) It further has been discovered that a single injection of morphogenic protein is sufficient to induce the desired biological effect, and that administration is not time-sensitive, provided mesenchymal progenitor cells are accessible to the defect site. That is, morphogenic protein can be provided to an individual having a local permissive defect site, shortly after creation of the defect, or at some significant time later, including, without limitation, after the initiation of fibrotic tissue formation. Thus, means now are available for enhancing restoration of tissue function and/or repair or regeneration of functional replacement tissue by systemically administering morphogenic protein, at times significantly after creation of the defect. The methods and formulations can be used to repair local defects without requiring surgical intervention; can enhance the rate and quality of new replacement tissue formation, particularly in compromised individuals with a reduced capacity to undergo spontaneous healing, and can be used to induce new tissue formation even after the initiation of fibrosis at the defect site. This discovery is disclosed in copending U.S. Patent Application filed on even date herewith, the disclosure of which is incorporated herein by reference.

Claims

1. A method for determining the morphogenic ability of a candidate morphogenic protein to induce new tissue formation at a local defect site at least 6 hours after tissue damage, comprising the steps of:

(a) creating a local defect site accessible to progenitor cells,

(b) administering at least 6 hours after creating the local defect site, said candidate morphogenic protein systemically to said mammal at a site distal from the local defect site, and

(c) measuring the amount of new tissue formation at said defect site,

wherein said local defect site is in renal, skeletal, lung, cardiac, liver, pancreas, uterine, ovarian, gastrointestinal, colon, dermal, osteochondral, chondral, or thyroid tissue, and

wherein said morphogenic protein is selected from the group consisting of;

OP1, OP2, OP3, BMP2, BMP3, BMP4, BMP5, BMP6, BMP9, BMP-10, BMP-11, BMP-12, BMP-15, BMP-3b, DPP, Vg1, Vgr-1, 60A protein, GDF-1, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, GDF-11, or amino acid sequence variants thereof;

or

wherein said candidate morphogenic protein comprises an amino acid sequence having at least 70% homology within the C-terminal 102 to 106 amino acids, including the conserved seven cysteine domain, of human OP1, and

wherein the amount of new tissue formation at said defect site measured in step (c) that is greater than the amount of new tissue formation measured in the absence of administration of said candidate morphogenic protein indicates the ability of said candidate morphogenic protein to induce new tissue formation at a local defect site at least 6 hours after tissue damage.

3. The method of claim 1 or 2, wherein said defect site occurs in renal tissue.

4. The method of claim 1 or 2, wherein said mammal is aged.

5. The method of claim 1 or 2, wherein said mammal has a reduced capacity to induce callus formation.

6. The method of claim 1 or 2, wherein said mammal is afflicted with impaired blood flow to the skeletal extremities.

7. The method of claim 1 or 2, wherein said mammal has a reduced capacity to induce an endogenous morphogenic signal.

8. The method of claim 1 or 2, wherein said morphogenic protein or analog thereof is administered parenterally.

9. The method of claim 8, wherein said morphogenic protein or analog thereof is administered intravenously.

10. The method of claim 1 or 2, wherein said morphogenic protein or analog thereof is administered orally.

11. The method of claim 1, wherein said morphogenic protein or analog thereof is administered to said mammal at a time when mesenchymal progenitor cells are accessible to said local defect site.

12. The method of claim 1, wherein said morphogenic protein or analog thereof is administered at least 24 hours after the creation of said local defect site.

13. The method of claim 1, wherein said morphogenic protein or analog thereof is administered at least 72 hours after the creation of said local defect site.

14. The method of claim 1 or 2, wherein said morphogenic protein or analog thereof is administered to said mammal after the initiation of fibrosis at said local defect site.

15. The method of claim 1 or 2, wherein said morphogenic protein or analog thereof is administered in aqueous solution.

16. The method of claim 4, wherein said mammal is a steroidal drug user.

17. The method of claim 4, wherein said mammal is aged, obese, hypertensive, or afflicted with osteopenia or diabetes.

18. The method of claim 1 or 2, wherein said morphogenic protein is OP1.

19. The method of claim 1 or 2, wherein said morphogenic protein is mature OP1 solubilized in a saline solution.

20. The method of claim 1 or 2, wherein said morphogenic protein comprises an amino acid sequence defined by OPX (SEQ ID No. 3);

Generic Sequence 6 (SEQ ID No.

     4), Generic Sequence 7 (SEQ ID No.

     5);

Generic Sequence 8 (SEQ ID No.

     6);

or Generic Sequence 9 (SEQ ID No.

     7).

21. The method of claim 1, wherein the ability of said candidate morphogenic protein or analog thereof to induce new tissue formation is measured by observation of actual new tissue formation by histological examination of the local defect site.

2. A method for determining an optimal dosage of a candidate morphogenic protein for administering to a mammal to induce new tissue formation at a local defect site at least 6 hours after tissue damage, comprising the steps of:

(a) creating a local defect site accessible to progenitor cells,

(b) administering at least 6 hours after creating the local defect site, said candidate morphogenic protein at a dosage to be tested systemically to said mammal at a site distal from the local defect site, and

(c) measuring the amount of new tissue formation at said defect site,

wherein said local defect site is in renal, skeletal, lung, cardiac, liver, pancreas, uterine, ovarian, gastrointestinal, colon, dermal, osteochondral, chondral, or thyroid tissue, and

wherein said morphogenic protein is selected from the group consisting of;

OP1, OP2, OP3, BMP2, BMP3, BMP4, BMP5, BMP6, BMP9, BMP-10, BMP-11, BMP-12, BMP-15, BMP-3b, DPP, Vg1, Vgr-1, 60A protein, GDF-1, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, GDF-11, or

wherein said candidate morphogenic protein comprises an amino acid sequence having at least 70% homology within the C-terminal 102 to 106 amino acids, including the conserved seven cysteine domain, of human OP1, and

wherein the dosage that induces the largest amount of new tissue formation at said defect site measured in step (c) indicates the optimal dosage of said candidate morphogenic protein to induce new tissue formation at a local defect site at least 6 hours after tissue damage.

22. A method for determining the tissue regeneration activity of a candidate morphogenic protein at least 6 hours after tissue damage, comprising the steps of:

(a) creating a local defect site accessible to progenitor cells,

(b) administering at least 6 hours after creating the local defect site, said candidate morphogenic protein systemically to said mammal at a site distal from the local defect site, and

(c) measuring the extent of replacement tissue regeneration at the local defect site, induced by the administration of said candidate morphogenic protein,

wherein said local defect site is in renal, skeletal, lung, cardiac, liver, pancreas, uterine, ovarian, gastrointestinal, colon, dermal, osteochondral, chondral, or thyroid tissue, and

wherein said morphogenic protein is selected from the group consisting of;

OP1, OP2, OP3, BMP2, BMP3, BMP4, BMP5, BMP6, BMP9, BMP-10, BMP-11, BMP-12, BMP-15, BMP-3b, DPP, Vg1, Vgr-1, 60A protein, GDF-1, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, GDF-11, or amino acid sequence variants thereof;

or

wherein said candidate morphogenic protein comprises an amino acid sequence having at least 70% homology within the C-terminal 102 to 106 amino acids, including the conserved seven cysteine domain, of human OP1, and

wherein the amount of tissue regeneration at said defect site measured in step (c) that is greater than the amount measured in the absence of administration of said candidate morphogenic protein indicates the tissue regeneration activity of a candidate morphogenic protein at least 6 hours after tissue damage.